Acquired skin-pulmonary syndromes
https://doi.org/10.18093/0869-0189-2025-35-5-706-713
Abstract
Lesions of the skin and its appendages against the background of respiratory diseases are fairly common in routine clinical practice. Abnormal changes in the skin and its appendages can manifest as signs of a multisystem genetic disease, chronic lung diseases, or acquired syndromes with combined lesions of the skin, its appendages, and respiratory organs. Abnormal changes in the skin and its appendages against the background of respiratory diseases can be linked to a severe systemic condition (Bazex syndrome, granulomatosis with polyangiitis, Löfgren’s syndrome), but at the same time can be the only clinical sign of the disease (yellow nail syndrome). The aim of this work is to describe the clinical features of acquired skin-pulmonary syndromes, including Bazex syndrome, granulomatosis with polyangiitis, Löfgren’s syndrome, yellow nail syndrome, eosinophilic granulomatosis with polyangiitis, and Sjogren syndrome, with an emphasis on the known clinical manifestations in the skin, its appendages and respiratory organs. Conclusion. Identification of distinct symptoms and syndromic nature of a specific disease is a very complex task, requiring deep academic and clinical knowledge of the physician. The variety of clinical lesions of the skin, its appendages, and respiratory organs associated with skin-pulmonary syndromes may create challenges during a routine appointment. In this article, the authors attempted to describe the main acquired skin-pulmonary syndromes encountered in the routine practice of both a pulmonologist and a dermatologist, with an emphasis on the clinical manifestations of these syndromes in the skin, its appendages, and respiratory organs.
About the Authors
T. A. Gosteva
“Kurchatov Center for Modern Medicine” Limited Liability Company
Russian Federation
Competing Interests:
Russian Federation
Tatyana A. Gosteva, Physician-Therapist, Pulmonologist, Deputy Chief Physician for Clinical and Expert Work; Member of the Kursk regional public organization “Society of Integrative Dermatology”
ul. Energetikov 10, Kursk region, Kurchatov, 307250, (908) 120-40-45
Competing Interests:
The authors have confirmed that they have no conflicts of interest to report.
R. V. Saranyuk
Cabinet of Dermatology and Venereology “Derma Expert”
Russian Federation
Competing Interests:
Russian Federation
Roman V. Saranyuk, Dermatovenerologist, Head; President, Kursk Regional Public Organization “Society of Integrative Dermatology”
prospect Anatoliya Deriglazova 1, office 3, Kursk, 305006, (910) 214-95-17
Competing Interests:
The authors have confirmed that they have no conflicts of interest to report.
References
1. Saad Abdalrazik F., Bedair N.I., Yassen N.N. Skin aging in patients with chronic obstructive pulmonary disease of different ages. Egypt. J. Chest Dis. Tuberc. 2021; 70 (3): 325–330. DOI: 10.4103/ejcdt.ejcdt_215_19.
2. Melzer T., Graf V., Kronseder A. et al. Skin markers of premature ageing in patients with COPD: results form COSYCONET. J. Clin. Med. 2024; 13 (22): 6972. DOI: 10.3390/jcm13226972.
3. Motswaledi M.H., Mayayise M.C. Nail changes in systemic diseases. S. Afr. Fam. Pract. 2010; 52 (5): 409–413. DOI: 10.1080/20786204.2010.10874016.
4. Federación Española de Enfermedades Raras. Available at: https://www.enfermedades-raras.org/enfermedades-raras [Accessed: January 6, 2022].
5. Birt A.R., Hogg G.R., Dubé W.J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 1977; 113 (12): 1674–1677. Available at: https://jamanetwork.com/journals/jamadermatology/article-abstract/538004
6. Cortini F., Villa C. Ehlers-Danlos syndromes and epilepsy: an updated review. Seizure. 2018; 57: 1–4. DOI: 10.1016/j.seizure.2018.02.013.
7. Solares I., Vinal D., Morales-Conejo M. Diagnostic and follow-up protocol for adult patients with neurofibromatosis type 1 in a Spanish reference unit. Rev. Clin. Esp. (Barc.). 2022; 222 (8): 486–495. DOI: 10.1016/j.rceng.2022.02.007.
8. Hyman M.H., Whittemore V.H. National Institutes of health consensus conference: tuberous sclerosis complex. Arch. Neurol. 2000; 57 (5): 662–665. DOI: 10.1001/archneur.57.5.662.
9. Naganathan S., Tadi P. Klippel–Trenaunay–Weber Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025: NBK558989. Available at: https://www.ncbi.nlm.nih.gov/books/NBK558989/
10. Berk D.R., Bentley D.D., Bayliss S.J. et al. Cutis laxa: a review. J. Am. Acad. Dermatol. 2012; 66 (5): 842.e1–17. DOI: 10.1016/j.jaad.2011.01.004.
11. Hermansky F., Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959; 14 (2): 162–169. Blood. 2016; 127 (14):1731. DOI: 10.1182/blood-2016-01-696435.
12. Dokal I. Dyskeratosis congenita in all its forms. Br. J. Haematol. 2000; 110 (4): 768–779. DOI: 10.1046/j.1365-2141.2000.02109.x.
13. Bazex A., Salvador R., Dupre A., Christol B. Syndrome paraneoplasieque a type d’hyperkeratose des extremites. Guerison apres le traitement de l’epithelioma larynge. Bull. Soc. Fr. Dermatol. Syphiligr. 1965; 72: 182.
14. Amano M., Hanafusa T., Chikazawa S. et al. Bazex syndrome in lung squamous cell carcinoma: high expression of epidermal growth factor receptor in lesional keratinocytes with Th2 immune shift. Case Rep. Dermatol. 2016; 8 (3): 358–362. DOI: 10.1159/000452827.
15. Bolognia J.L., Brewer Y.P., Cooper D.L. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991; 70 (4): 269–280. DOI: 10.1097/00005792-199107000-00004.
16. Eckstein J., Healy E., Jain A. et al. A series of typical and atypical cases of Bazex syndrome: Identifying the red herring to avoid delaying cancer treatment. Clin. Case Rep. 2020; 8 (11): 2259–2264. DOI: 10.1002/ccr3.3133.
17. Stone S.P., Buescher L.S. Life-threatening paraneoplastic cutaneous syndromes. Clin. Dermatol. 2005; 23 (3): 301–306. DOI: 10.1016/j.clindermatol.2004.06.011.
18. Bazex A., Griffiths A. Acrokeratosis paraneoplastica – a new cutaneous marker of malignancy. Br. J. Dermatol. 1980; 103 (3): 301–306. DOI: 10.1111/j.1365-2133.1980.tb07248.x.
19. Sharma V., Sharma N.L., Ranjan N. et al. Acrokeratosis paraneoplastica (Bazex syndrome): case report and review of literature. Dermatol. Online J. 2006; 12 (1): 11. DOI: 10.5070/D34fz6f008.
20. Zarzour J.G., Singh S., Andea A., Cafardi J.A. Acrokeratosis paraneoplastica (Bazex syndrome): report of a case associated with small cell lung carcinoma and review of the literature. J. Radiol. Case Rep. 2011; 5 (7): 1–6. DOI: 10.3941/jrcr.v5i7.663.
21. Hsu Y.S., Lien G.S., Lai H.H. et al. Acrokeratosis paraneoplastica (Bazex syndrome) with adenocarcinoma of the colon: report of a case and review of the literature. J. Gastroenterol. 2000; 35 (6): 460–464. DOI: 10.1007/s005350070092.
22. Hempen A., Samartzis E.P., Kamarachev J. et al. Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report. BMC Cancer. 2015; 15: 507. DOI: 10.1186/s12885-015-1527-z.
23. Mititelu R., Powell M. A case report of resolution of acrokeratosis paraneoplastica (Bazex syndrome) post resection of non-small-cell lung carcinoma. SAGE Open Med. Case Rep. 2019; 7: 2050313X19881595. DOI: 10.1177/2050313X19881595.
24. Pecora A.L., Landsman L., Imgrund S.P., Lambert W.C. Acrokeratosis paraneoplastica (Bazex' syndrome). Report of a case and review of the literature. Arch. Dermatol. 1983; 119 (10): 820-826. DOI: 10.1001/archderm.119.10.820.
25. Ikeda K., Kanno K., Otani Y., Ito M. A case of Bazex syndrome. Intern Med. 2022; 61 (3): 443–444. DOI: 10.2169/internalmedicine.7568-21.
26. Aoshima Y., Karayama M., Sagisaka S. et al. Synchronous occurrence of Bazex syndrome and remitting seronegative symmetrical synovitis with pitting edema syndrome in a patient with lung cancer. Intern Med. 2019, 58 (22): 3267–3271. DOI: 10.2169/internalmedicine.3032-19.
27. Zhao J., Zhang X., Chen Z., Wu J.H. Case report: Bazex syndrome associated with pulmonary adenocarcinoma. Medicine (Baltimore). 2016; 95 (2): e2415. DOI: 10.1097/MD.0000000000002415.
28. George C., Diaz-Cano S., Creamer D. An unusual cause for a psoriasiform dermatosis. Clin. Exp. Dermatol. 2017; 42 (1): 115–117. DOI: 10.1111/ced.12992.
29. Fleming J.D., Stefanato C.M., Attard N.R. Bazex syndrome (acrokeratosis paraneoplastica). Clin. Exp. Dermatol. 2014; 39 (8): 955–956. DOI: 10.1111/ced.12353.
30. Humphrey S.R., Hussain A.S., Chandran R. et al. Acute onset of acrokeratosis paraneoplastica (Bazex syndrome). JAMA Dermatol. 2015; 151 (6): 677–678. DOI: 10.1001/jamadermatol.2014.5622.
31. Dabas G., De D., Handa S. et al. Acrokeratosis paraneoplastica (Bazex syndrome). QJM. 2018; 111 (1): 63–64. DOI: 10.1093/qjmed/hcx187.
32. Peixoto L., Aguiar P., Veloso Gomes F. et al. Nogueira Wegener’s granulomatosis. In: Amezcua-Guerra L.M., ed. Advances in the etiology, pathogenesis and pathology of vasculitis. IntechOpen; 2011; Ch. 11: 225–234. DOI: 10.5772/20014.
33. Klinger H. Grenzformen der pericarditis nodosa. Frankfurt Zeitschr Pathol. 1931; 42: 455–480.
34. Fauci A.S., Wolff S.M. Wegener´s granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973; 52 (6): 535–561. DOI: 10.1097/00005792-197311000-00002.
35. Kallenberg C.G. Pathogenesis of ANCA-associated vasculitides. Ann. Rheum. Dis. 2011; 70 (Suppl. 1): i59–63. DOI: 10.1136/ard.2010.138024.
36. Jayne D. The diagnosis of vasculitis. Best Pract. Res. Clin. Rheumatol. 2009; 23 (3): 445–453. DOI: 10.1016/j.berh.2009.03.001.
37. Manganelli P., Fietta P., Carotti M. et al. Respiratory system involvement in systemic vasculitides. Clin. Exp. Rheumatol. 2006; 24 (2, Suppl. 41): S48–59. Available at: https://www.clinexprheumatol.org/abstract.asp?a=2846
38. Merkel P.A., Lo G.H., Holbrook J.T. et al. Wegener's granulomatosis etanercept trial research group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann. Intern Med. 2005; 142 (8): 620–626. DOI: 10.7326/0003-4819-142-8-200505030-00011.
39. Harper S.L., Letko E., Samson C.M. et al. Wegener's granulomatosis: the relationship between ocular and systemic disease. J. Rheumatol. 2001; 28 (5): 1025–1032. Available at: https://www.jrheum.org/content/28/5/1025
40. Shafiei K., Luther E., Archie M. et al. Wegener granulomatosis: case report and brief literature review. J. Am. Board Fam. Pract. 2003; 16 (6): 555–559. DOI: 10.3122/jabfm.16.6.555.
41. Ungprasert P., Crowson C.S., Matteson E.L. Clinical characteristics of sarcoid arthropathy: a population-based study. Arthritis Care Res. (Hoboken). 2016; 68 (5): 695–699. DOI: 10.1002/acr.22737.
42. Visser H., Vos K., Zanelli E. et al. Sarcoid arthritis: clinical characteristics, diagnostic aspects, and risk factors. Ann. Rheum. Dis. 2002; 61 (6): 499–504. DOI: 10.1136/ard.61.6.499.
43. Llanos O., Hamzeh N. Sarcoidosis. Med. Clin. North Am. 2019; 103 (3): 527–534. DOI: 10.1016/j.mcna.2018.12.011.
44. Lofgren S. Primary pulmonary sarcoidosis. I. Early signs and symptoms. Acta Med. Scand. 1953; 145 (6): 424–431. DOI: 10.1111/j.0954-6820.1953.tb07039.x.
45. Flores R., Caridade S. Löfgren syndrome: clinical presentation, clinical course, and literature review. Cureus. 2023; 15 (1): e33651. DOI: 10.7759/cureus.33651.
46. Debashis M., Amrita P., Pratima S., Prasanta P. Lofgren syndrome: not an uncommon entity. J. Int. Med. Res. 2023; 1 (1): 25–28. DOI: 10.4103/jimr.jimr_5_22.
47. Wanat K.A., Rosenbach M. Cutaneous sarcoidosis. Clin. Chest Med. 2015; 36 (4): 685–702. DOI: 10.1016/j.ccm.2015.08.010.
48. Arthritis in sarcoidosis group (ASG); Agarwal V., Agrawal V., Aggarwal A. et al. Arthritis in sarcoidosis: a multicentric study from India. Int. J. Rheum. Dis. 2018; 21 (9): 1728–1733. DOI: 10.1111/1756-185X.13349.
49. Rochepeau C., Jamilloux Y., Kerever S. et al. Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis. Br. J. Ophthalmol. 2017; 101 (7): 856–861. DOI: 10.1136/bjophthalmol-2016-309767.
50. Hiller E., Rosenow E.C. 3rd, Olsen A.M. Pulmonary manifestations of the yellow nail syndrome. Chest. 1972; 61 (5): 452–458. DOI: 10.1378/chest.61.5.452.
51. Heller J. Die krankheiten der nägel. Berlin: Springer. 1927; 13 (Pt 2). DOI: 10.1007/978-3-642-91683-0.
52. Samman P.D., White W.F. The “Yellow nail” syndrome. Br. J. Dermatol. 1964; 76: 153–157. DOI: 10.1111/j.1365-2133.1964.tb14499.
53. Maldonado F., Ryu J.H. Yellow nail syndrome. Curr. Opin. Pulm. Med. 2009; 15 (4): 371–375. DOI: 10.1097/MCP.0b013e32832ad45a.
54. Decker A., Daly D., Scher R.K. Role of titanium in the development of yellow nail syndrome. Skin. Appendage Disord. 2015; 1 (1): 28–30. DOI: 10.1159/000375171.
55. Piraccini B.M., Urciuoli B., Starace M. et al. Yellow nail syndrome: clinical experience in a series of 21 patients. J. Dtsch. Dermatol. Ges. 2014; 12 (2): 131–137. DOI: 10.1111/ddg.12216.
56. Nordkild P., Kromann-Andersen H., Struve-Christensen E. Yellow nail syndrome – the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med. Scand. 1986; 219 (2): 221–227. DOI: 10.1111/j.0954-6820.1986.tb03302.x.
57. Varney V.A., Cumberworth V., Sudderick R. et al. Rhinitis, sinusitis and the yellow nail syndrome: a review of symptoms and response to treatment in 17 patients. Clin. Otolaryngol. Allied. Sci. 1994; 19 (3): 237–240. DOI: 10.1111/j.1365-2273.1994.tb01222.x.
58. Pavlidakey G.P., Hashimoto K., Blum D. Yellow nail syndrome. J. Am. Acad. Dermatol. 1984; 11 (3): 509–512. DOI: 10.1016/s0190-9622(84)70201-5.
59. Maisels D.O., Korachi A.O. Lymphoedema of the eyelids in the yellow nail syndrome. Br. J. Plast Surg. 1985; 38 (1): 93–96. DOI: 10.1016/0007-1226(85)90093-1.
60. Bourcier T., Baudrimont M., Borderie V. et al. Conjunctival changes associated with yellow nail syndrome. Br. J. Ophthalmol. 2002; 86 (8): 930. DOI: 10.1136/bjo.86.8.930.
61. Gosteva T.A., Kleuzovich V.M., Saraniuk R.V. [Yellow nail syndrome: a series of two clinical cases and review of the literature]. Vestnik dermatologii i venerologii. 2024; 100 (5): 89–96. DOI: 10.25208/vdv16771 (in Russian).
62. Stosiek N., Peters K.P., Hiller D. et al. Yellow nail syndrome in a patient with mycosis fungoides. J. Am. Acad. Dermatol. 1993; 28 (5, Pt 1): 792–794. DOI: 10.1016/s0190-9622(09)80277-6.
63. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol. 1951; 27 (2): 277–301. Available at: https://scispace.com/papers/allergic-granulomatosis-allergic-angiitis-and-periarteritis-4mmqsaji3q
64. Jennette J.C., Falk R.J., Andrassy K. et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37 (2): 187–192. DOI: 10.1002/art.1780370206.
65. Chakraborty R.K., Aeddula N.R. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537099/
66. Knockaert D.C. Cardiac involvement in systemic inflammatory diseases. Eur. Heart J. 2007; 28 (15): 1797–1804. DOI: 10.1093/eurheartj/ehm193.
67. Boggi U., Mosca M., Giulianotti P.C. et al. Surviving catastrophic gastrointestinal involvement due to Churg–Strauss syndrome: report of a case. Hepatogastroenterology. 1997; 44 (16): 1169–1171.
68. Pagnoux C., Guillevin L. Churg–Strauss syndrome: evidence for disease subtypes? Curr. Opin. Rheumatol. 2010; 22 (1): 21–28. DOI: 10.1097/BOR.0b013e328333390b.
69. Ewert B.H., Jennette J.C., Falk R.J. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int. 1992; 41 (2): 375–383. DOI: 10.1038/ki.1992.52.
70. Oiwa H., Mokuda S., Matsubara T. et al. Neurological complications in eosinophilic granulomatosis with polyangiitis (EGPA): the roles of history and physical examinations in the diagnosis of EGPA. Intern. Med. 2017; 56 (22): 3003–3008. DOI: 10.2169/internalmedicine.8457-16.
71. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjögren's syndrome. Autoimmun. Rev. 2010; 9 (5): A305–A310. DOI: 10.1016/j.autrev.2009.11.004.
72. Skopouli F.N., Dafni U., Ioannidis J.P., Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin. Arthritis Rheum. 2000; 29 (5): 296–304. DOI: 10.1016/s0049-0172(00)80016-5.
73. Papiris S.A., Maniati M., Constantopoulos S.H. et al. Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann. Rheum. Dis. 1999; 58 (1): 61–64. DOI: 10.1136/ard.58.1.61.
74. Papiris S.A., Tsonis I.A., Moutsopoulos H.M. Sjogren's syndrome. Semin. Respir. Crit. Care Med. 2007; 28: 459–471. DOI: 10.1055/s-2007-985667.
75. Mavragani C.P., Moutsopoulos H.M. Sjögren syndrome. CMAJ. 2014; 186 (15): E579–586. DOI: 10.1503/cmaj.122037.
76. Tsokos M., Lazarou S.A., Moutsopoulos H.M. Vasculitis in primary Sjögren's syndrome. Histologic classification and clinical presentation. Am. J. Clin. Pathol. 1987; 88 (1): 26–31. DOI: 10.1093/ajcp/88.1.26.
77. Ramos-Casals M., Anaya J.M., García-Carrasco M. et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004; 83 (2): 96–106. DOI: 10.1097/01.md.0000119465.24818.98.
78. Skopouli F.N., Talal A., Galanopoulou V. et al. Raynaud's phenomenon in primary Sjögren's syndrome. J. Rheumatol. 1990; 17 (5): 618–620.
79. Tsampoulas C.G., Skopouli F.N., Sartoris D.J. et al. Hand radiographic changes in patients with primary and secondary Sjögren's syndrome. Scand. J. Rheumatol. 1986; 15 (3): 333–339. DOI: 10.3109/03009748609092600.
80. Kassan S.S., Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjögren syndrome. Arch. Intern. Med. 2004; 164 (12): 1275–1284. DOI: 10.1001/archinte.164.12.1275.
81. Skopouli F.N., Barbatis C., Moutsopoulos H.M. Liver involvement in primary Sjögren's syndrome. Br. J. Rheumatol. 1994; 33 (8): 745–748. DOI: 10.1093/rheumatology/33.8.745.
82. Goules A., Masouridi S., Tzioufas A.G. et al. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore). 2000; 79 (4): 241–249. DOI: 10.1097/00005792-200007000-00005.
83. Mavragani C.P., Fragoulis G.E., Moutsopoulos H.M. Endocrine alterations in primary Sjogren's syndrome: an overview. J. Autoimmun. 2012; 39 (4): 354–358. DOI: 10.1016/j.jaut.2012.05.011.
84. Brito-Zerón P., Akasbi M., Bosch X. et al. Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren's syndrome. Clin. Exp. Rheumatol. 2013; 31 (1): 103–110. Available at: https://www.clinexprheumatol.org/abstract.asp?a=5938
85. Pavlakis P.P., Alexopoulos H., Kosmidis M.L. et al. Peripheral neuropathies in Sjogren syndrome: a new reappraisal. J. Neurol. Neurosurg Psychiatry. 2011; 82 (7): 798–802. DOI: 10.1136/jnnp.2010.222109.
86. Voulgarelis M., Ziakas P.D., Papageorgiou A. et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore). 2012; 91 (1): 1–9. DOI: 10.1097/MD.0b013e31824125e4.
Supplementary files
Review
For citations:
Gosteva T.A., Saranyuk R.V. Acquired skin-pulmonary syndromes. PULMONOLOGIYA. 2025;35(5):706-713. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-5-706-713
Views:
59
Email this article 